Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide Duration Before Denosumab in Osteoporosis
NCT03702140Phase 2Unknown
- Sponsor
- Shinshu University
- Start
- Oct 2018
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of teriparatide in osteoporosis, sponsored by Shinshu University. Primary endpoint: Bone mineral density at 1 year. Status: unknown.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03702140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702140.